Loperamide HCl - CAS 34552-83-5
Catalog number: 34552-83-5
Category: Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
Molecular Weight:
Opioid Receptor
Loperamide HCl is an opioid-receptor agonist with an ED50 of 0.15 mg/kg.
Publictions citing BOC Sciences Products
  • >> More
ADL 2-1294
1.Diagnosis and treatment of diarrhea-predominant irritable bowel syndrome.
Lacy BE1. Int J Gen Med. 2016 Feb 11;9:7-17. doi: 10.2147/IJGM.S93698. eCollection 2016.
Irritable bowel syndrome (IBS) is one of the most common gastrointestinal disorders worldwide. The economic impact of IBS on the health care system is substantial, as is the personal impact on patients. Patients with diarrhea-predominant IBS (IBS-D) comprise a substantial proportion of the overall IBS population. Primary care providers are often the first point of contact for patients with IBS-D and can accurately diagnose IBS after a careful history and examination without extensive diagnostic tests. Several pharmacologic treatments (eg, loperamide, alosetron, and antidepressants) and non-pharmacologic treatments (eg, dietary modification and probiotics) are available for IBS-D, but restrictions on use (eg, alosetron) or the lack of controlled trial data showing reductions in both global and individual IBS-D symptoms (eg, bloating, pain and stool frequency) emphasize the need for alternative treatment options. Two newer medications (eluxadoline and rifaximin) were approved in May 2015 for the treatment of IBS-D, and represent new treatment options for this common gastrointestinal condition.
2.Not your regular high: cardiac dysrhythmias caused by loperamide.
Wightman RS1, Hoffman RS1, Howland MA1,2, Rice B3, Biary R1, Lugassy D1. Clin Toxicol (Phila). 2016 Mar 29:1-5. [Epub ahead of print]
OBJECTIVE: Loperamide, a non-prescription anti-diarrheal agent, is a peripheral mu-opioid receptor agonist that is excluded from the blood-brain barrier by p-glycoprotein at therapeutic doses. Overdoses of loperamide penetrate the central nervous system (CNS), leading to abuse. We report cardiac conduction abnormalities and dysrhythmias after ingestion of a recreational supra-therapeutic dose of loperamide confirmed with an elevated blood loperamide concentration.
3.Proactive management strategies for potential gastrointestinal adverse reactions with ceritinib in patients with advanced ALK-positive non-small-cell lung cancer.
Schaefer ES1, Baik C2. Cancer Manag Res. 2016 Mar 24;8:33-8. doi: 10.2147/CMAR.S96471. eCollection 2016.
Anaplastic lymphoma kinase (ALK) gene fusions occur in 3%-7% of non-small-cell lung cancer (NSCLC) cases. Ceritinib, a once-daily, oral ALK inhibitor, has activity against crizotinib-resistant and crizotinib-naïve NSCLC, including brain metastases. Ceritinib (Zykadia™) was granted accelerated approval by the US Food and Drug Administration in 2014 for treating crizotinib-resistant ALK-positive NSCLC. Adverse events (AEs), particularly gastrointestinal (GI) AEs, are commonly experienced at the recommended dose of 750 mg/d and ∼38% of patients require dose interruption or reduction for GI AEs. This case study details our experience with the use of proactive GI AE management regimens in patients treated with ceritinib (750 mg/d) across two study sites. Proactive Regimens A and B were implemented in patients with metastatic ALK-positive NSCLC treated with ceritinib to manage drug-related GI AEs. Regimen A comprised ondansetron and diphenoxylate/atropine or loperamide, taken 30 minutes prior to ceritinib dose.
4.Evaluation of antidiarrheal activity of ethanolic extract of Holarrhena antidysenterica seeds in rats.
Sharma DK1, Gupta VK1, Kumar S1, Joshi V1, Mandal RS1, Prakash AG1, Singh M1. Vet World. 2015 Dec;8(12):1392-5. doi: 10.14202/vetworld.2015.1392-1395. Epub 2015 Dec 11.
AIM: The present study was conducted to evaluate the antidiarrheal effect of ethanolic extract of Holarrhena antidysenterica (Family - Apocynaceae) seeds against induced diarrhea in Wistar albino rats.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Opioid Receptor Products

CAS 83420-94-4 ICI 154,129

ICI 154,129
(CAS: 83420-94-4)

ICI 154,129 is a selective δ opioid antagonist. It is a peptide analog that antagonized the effects of Leu-enkephalin.

(CAS: 854601-70-0)

Naloxegol is a CYP3A4 enzyme inhibitor. It is also a peripherally-selective opioid antagonist. It is used as the treatment of opioid-induced constipation. lt is...

CAS 112465-94-8 U-54494A hydrochloride

U-54494A hydrochloride
(CAS: 112465-94-8)

U-54494A hydrochloride is a κ-opioid agonist and a potential NMDA antagonist. U-54494A hydrochloride is used as an anticonvulsant.

CAS 126766-32-3 GR 89696 fumarate

GR 89696 fumarate
(CAS: 126766-32-3)

GR 89696 fumarate is a potent and selective κ-opioid agonist (IC50 = 0.04 nM) displaying anti-nociceptive and neuroprotective activity.

CAS 114528-79-9 (-)-U-50488 hydrochloride

(-)-U-50488 hydrochloride
(CAS: 114528-79-9)

(-)-U-50488 hydrochloride is the more active enantiomer of (±)-U-50488, which is an opioid receptor agonist.

CAS 83397-56-2 PL 017

PL 017
(CAS: 83397-56-2)

PL 017, a morphiceptin analog, is a selective μ opioid receptor agonist (IC50= 5.5 and > 10000 nM for inhibition of 125I-FK 33,824 and 125I-DADLE binding to μ a...

CAS 267234-08-2 [Nphe1]Nociceptin(1-13)NH2

(CAS: 267234-08-2)

[Nphe1]Nociceptin(1-13)NH2 acts as the first truly selective and competitive nociceptin receptor antagonist and is devoid of any residual agonist activity. It b...

CAS 85951-63-9 FIT

(CAS: 85951-63-9)

FIT is a selective and irreversible δ-opioid (DOR) agonist (EC50 = 8 nM).

CAS 188119-47-3 NocII

(CAS: 188119-47-3)

NocII, a heptadecapeptide whose sequence lies immediately downstream of nociceptin, stimulates locomotion in mice, possibly through a novel specific receptor.

CAS 155836-50-3 BW 373U86

BW 373U86
(CAS: 155836-50-3)

BW 373U86 is a potent and selective non-peptide δ-opioid receptor agonist (Ki = 1.8, 15 and 34 nM for δ, μ and κ receptors, respectively).

CAS 1997387-43-5 PZM21

(CAS: 1997387-43-5)

PZM21 is a potent Gi activator with exceptional selectivity for μOR (EC50= 1.8 nM) and minimal β-arrestin-2 recruitment.

CAS 16676-29-2 Naltrexone HCl

Naltrexone HCl
(CAS: 16676-29-2)

Naltrexone significantly suppresses ethanol self-administration and prevents ethanol-induced increases in dialysate dopamine levels.

CAS 118111-54-9 Cyprodime hydrochloride

Cyprodime hydrochloride
(CAS: 118111-54-9)

Cyprodime hydrochloride is a selective μ-opioid receptor antagonist from the morphinan family of drugs. Its Ki values are 5.4, 244.6 and 2187 nM for μ-, δ- and ...

CAS 20410-95-1 6 α-naloxol

6 α-naloxol
(CAS: 20410-95-1)

6 α-naloxol, a human metabolite of naloxone, is an opioid antagonist.

CAS 113158-34-2 nor-Binaltorphimine dihydrochloride

nor-Binaltorphimine dihydrochloride
(CAS: 113158-34-2)

nor-Binaltorphimine dihydrochloride is a selective κ-opioid receptor antagonist.

CAS 361444-66-8 JDTic

(CAS: 361444-66-8)

A 4-phenylpiperidine derivative, for the κ-opioid receptor.

CAS 1355244-02-8 ML 190

ML 190
(CAS: 1355244-02-8)

ML 190 is a κ opioid receptor antagonist with IC50 value of 120 nM.

CAS 58822-25-6 [Leu5]-Enkephalin

(CAS: 58822-25-6)

[Leu5]-Enkephalin is an endogenous opioid agonist peptide with morphine-like activity. It inhibits electrically stimulated contractions in mouse vas deferens (I...

CAS 67197-96-0 (±)-U-50488 hydrochloride

(±)-U-50488 hydrochloride
(CAS: 67197-96-0)

(±)-U-50488 hydrochloride is a selective κ-opioid agonist with no μ-opioid antagonist effects. (±)-U-50488 hydrochloride blocks Na+ channels at high concentrati...

CAS 155512-52-0 DIPPA hydrochloride

DIPPA hydrochloride
(CAS: 155512-52-0)

DIPPA hydrochloride is an irreversible and selective antagonist of κ-opioid receptor (KOR).

Chemical Structure

CAS 34552-83-5 Loperamide HCl

Quick Inquiry

Verification code

Featured Items